EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Sinopharm Group Co's Enterprise Value is €15,654 Mil.
Sinopharm Group Co's Free Cash Flow for the trailing twelve months (TTM) ended in Jun. 2024 was €2,164 Mil. Therefore, Sinopharm Group Co's EV-to-FCF for today is 7.23.
The historical rank and industry rank for Sinopharm Group Co's EV-to-FCF or its related term are showing as below:
FRA:X2S'
s EV-to-FCF Range Over the Past 10 Years
Min: 5.43 Med: 12.04 Max: 538.93
Current: 6.88
During the past 13 years, the highest EV-to-FCF of Sinopharm Group Co was 538.93. The lowest was 5.43. And the median was 12.04.
FRA:X2S's EV-to-FCF is ranked better than 73.97% of 73
companies
in the Medical Distribution industry
Industry Median: 14.19
vs FRA:X2S: 6.88
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
The historical data trend for Sinopharm Group Co's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Sinopharm Group Co's EV-to-FCF
For the Medical Distribution subindustry, Sinopharm Group Co's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sinopharm Group Co's EV-to-FCF Distribution in the Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, Sinopharm Group Co's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Sinopharm Group Co's EV-to-FCF falls into.
Sinopharm Group Co's current Enterprise Value is €15,654 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Sinopharm Group Co's Free Cash Flow for the trailing twelve months (TTM) ended in Jun. 2024 was €2,164 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sinopharm Group Co (FRA:X2S) EV-to-FCF Explanation
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Sinopharm Group Co's PE Ratio (TTM) for today is calculated as:
Sinopharm Group Co's share price for today is €2.196.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Sinopharm Group Co's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Jun. 2024 was €0.292.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Sinopharm Group Co EV-to-FCF Related Terms
Thank you for viewing the detailed overview of Sinopharm Group Co's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.
Founded in 2003, Sinopharm is the largest wholesaler and retailer of drugs and medical devices in China and listed on the Hong Kong Stock Exchange in 2009. It is a core subsidiary of China National Pharmaceutical Group. Sinopharm's largest operating segment is pharmaceutical distribution, making up over 70% of its total revenue by the end of 2023. In 2018, Sinopharm acquired the largest Chinese medical device distributor, China National Scientific Instruments and Materials. Now, medical device distribution accounts for over 20% of Sinopharm's total revenue. Sinopharm's downstream customers range from hospitals and other health services institutions to end-customers.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
FRA:X2S has been successfully added to your 